Therefore, PRMT1 and PRMT6 may be a promising target for bladder cancer therapy, and their inhibitors may be ideal candidates for molecular targeted therapy of bladder cancer (43). This evidence concerns the gene PRMT6 and urinary bladder carcinoma.